Physician profile
Lev Aminov
NPI 1033317888
$41,056.52
in general payments reported to CMS, 2019-2025
42 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,229 · 2020: $6,649 · 2021: $8,838 · 2022: $9,163 · 2023: $8,653 · 2024: $1,309 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,157.54 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,356.01 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $4,362.52 | 2019-2024 | Qulipta, Linzess, Ubrelvy |
| Novo Nordisk INC | $3,168.99 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $2,886.52 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,540.80 | 2019-2024 | Cycloset, Trulance, Xifaxan |
| Regeneron Healthcare Solutions, INC. | $2,089.71 | 2019-2024 | Dupixent |
| Genzyme Corporation | $1,932.51 | 2020-2024 | |
| Esperion Therapeutics, INC. | $1,602.31 | 2020-2024 | Nexletol |
| Pfizer INC. | $1,561.55 | 2019-2024 | |
| Horizon Therapeutics Plc | $1,295.58 | 2019-2022 | |
| Amarin Pharma, INC. | $1,205.35 | 2019-2023 | |
| Abbott Laboratories | $1,161.13 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $1,053.77 | 2019-2024 | Livalo, Seglentis |
| Ironwood Pharmaceuticals, INC | $929.37 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $858.30 | 2019-2024 | Eliquis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lev Aminov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.